Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results.

Autor: Cortes JE; Georgia Cancer Center at Augusta University, Augusta, GA, USA. Jorge.Cortes@Augusta.edu., Sasaki K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kim DW; Uijeongbu Eulji Medical Center, Geumo-dong, Uijeongbu-si, South Korea., Hughes TP; South Australian Health and Medical Research Institute and University of Adelaide, Adelaide, SA, Australia., Etienne G; Department of Hematology, Institut Bergonié, Bordeaux, France., Mauro MJ; Myeloproliferative Neoplasms Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Hochhaus A; Hematology/Oncology, Universitätsklinikum Jena, Jena, Germany., Lang F; Department of Medicine, Hematology and Oncology, Goethe University Hospital, Frankfurt, Germany., Heinrich MC; Portland VA Health Care System and OHSU Department of Medicine, Division of Hematology and Oncology, Knight Cancer Institute, Portland, OR, USA., Breccia M; Department of Translational and Precision Medicine-Az., Policlinico Umberto I-Sapienza University, Rome, Italy., Deininger M; Versiti Blood Research Institute, Milwaukee, WI, USA., Goh YT; Department of Haematology, Singapore General Hospital, Bukit Merah, Singapore., Janssen JJWM; Radboud University Medical Center, Nijmegen, The Netherlands., Talpaz M; Division of Hematology-Oncology, University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA., de Soria VGG; Hospital Universitario La Princesa, Madrid, Spain., le Coutre P; Department of Oncology and Hematology, Charité - Universitätsmedizin Berlin, Berlin, Germany., DeAngelo DJ; Dana-Farber Cancer Institute, Boston, MA, USA., Damon A; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Cacciatore S; Novartis Pharma AG, Basel, Switzerland., Polydoros F; Novartis Pharma AG, Basel, Switzerland., Agrawal N; Novartis Pharma AG, Basel, Switzerland., Rea D; Department of Hématologie, Hôpital Saint-Louis, Paris, France.

Publikováno v: Leukemia [Leukemia] 2024 Jul; Vol. 38 (7), pp. 1522-1533. Date of Electronic Publication: 2024 May 16.

BCR::ABL1 digital PCR for treatment-free remission prediction in chronic myeloid leukemia patients: An individual participant data meta-analysis.

Autor: Kockerols C; Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands., Valk PJM; Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands., Dulucq S; Laboratory of Hematology, Hôpital Haut Lévêque, University hospital of Bordeaux, Pessac, France., Nicolini FE; Department of Hematology, Centre Léon Bérard and CRCL, Lyon, France., Mahon FX; Department of Hematology, Institut Bergonié, Bordeaux, France.; INSERM Unit BRIC 1312, Bordeaux University, Bordeaux, France., Atallah E; Department of Internal Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA., Mauro MJ; Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Radich JP; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA., Bernardi S; Department of Clinical and Experimental Sciences, Hematology 2 and Bone Marrow Transplant Center, University of Brescia, ASST Spedali Civili of Brescia, Brescia, Italy., Russo D; Department of Clinical and Experimental Sciences, Hematology 2 and Bone Marrow Transplant Center, University of Brescia, ASST Spedali Civili of Brescia, Brescia, Italy., Farina M; Department of Clinical and Experimental Sciences, Hematology 2 and Bone Marrow Transplant Center, University of Brescia, ASST Spedali Civili of Brescia, Brescia, Italy., Mori S; Department of Medicine and Surgery, University of Milano Bicocca, Monza, Italy., Gambacorti-Passerini C; Department of Medicine and Surgery, University of Milano Bicocca, Monza, Italy.; Department of Hematology, S. Gerardo Hospital, Monza, Italy., Civettini I; Department of Medicine and Surgery, University of Milano Bicocca, Monza, Italy.; Department of Hematology, S. Gerardo Hospital, Monza, Italy., Lu L; South Australia Health and Medical Research Institute, University of Adelaide Medical School and Precision Cancer Medicine Theme, Adelaide, Australia., Yeung D; South Australia Health and Medical Research Institute, University of Adelaide Medical School and Precision Cancer Medicine Theme, Adelaide, Australia., Branford S; Department of Genetics and Molecular Pathology, Centre for Cancer Biology, SA Pathology, Adelaide, Australia.; Clinical and Health Sciences, University of South Australia, Adelaide, Australia.; School of Medicine, The University of Adelaide, Adelaide, Australia., Colafigli G; Department of Translational and Precision Medicine, Az. Policlinico Umberto I-Sapienza University, Rome, Italy., Breccia M; Department of Translational and Precision Medicine, Az. Policlinico Umberto I-Sapienza University, Rome, Italy., Hogenbirk P; Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands., van Rosmalen J; Department of Biostatistics, Erasmus University Medical Center, Rotterdam, The Netherlands.; Department of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands., Cornelissen JJ; Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands., Westerweel PE; Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands.

Publikováno v: American journal of hematology [Am J Hematol] 2024 Aug; Vol. 99 (8), pp. 1632-1635. Date of Electronic Publication: 2024 May 20.

Estimated Savings After Stopping Tyrosine Kinase Inhibitor Treatment Among Patients With Chronic Myeloid Leukemia.

Autor: Winn AN; Department of Health Systems, Outcomes and Policy, School of Pharmacy, University of Illinois at Chicago., Atallah E; Department of Medicine, Medical College of Wisconsin, Milwaukee., Cortes J; Georgia Cancer Center, Augusta University Medical Center, Augusta., Deininger MWN; Department of Medicine, Medical College of Wisconsin, Milwaukee., Kota V; Georgia Cancer Center, Augusta University Medical Center, Augusta., Larson RA; Department of Medicine and Comprehensive Cancer Center, University of Chicago, Chicago, Illinois., Moore JO; Duke University School of Medicine, Durham, North Carolina., Mauro MJ; Memorial Sloan Kettering Cancer Center, New York, New York., Oehler VG; Fred Hutchinson Cancer Research Center, Seattle, Washington., Pinilla-Ibarz J; H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida., Radich JP; Fred Hutchinson Cancer Research Center, Seattle, Washington., Shah NP; Department of Medicine, University of California at San Francisco., Thompson JE; Roswell Park Comprehensive Cancer Center, Buffalo, New York., Flynn KE; Department of Medicine, Medical College of Wisconsin, Milwaukee.

Publikováno v: JAMA network open [JAMA Netw Open] 2023 Dec 01; Vol. 6 (12), pp. e2347950. Date of Electronic Publication: 2023 Dec 01.

Treatment-free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response: Final 5-year analysis of DASFREE.

Autor: Shah NP; UCSF School of Medicine, San Francisco, California, USA., García-Gutiérrez V; Servicio Hematología y Hemoterapia, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain., Jiménez-Velasco A; Servicio de Hematología y Hemoterapia, Hospital Regional Universitario de Málaga, IBIMA, Málaga, Spain., Larson SM; David Geffen School of Medicine at UCLA, Los Angeles, California, USA., Saussele S; Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany., Rea D; Adult Hematology Department, Hôpital Saint-Louis, Paris, France., Mahon FX; Institut Bergonié Cancer Center, Université Bordeaux, Bordeaux, France., Levy MY; Baylor Charles A. Sammons Cancer Center, Dallas, Texas, USA., Gómez-Casares MT; Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain., Mauro MJ; Memorial Sloan Kettering Cancer Center, New York, New York, USA., Sy O; Bristol Myers Squibb, Princeton, New Jersey, USA., Martin-Regueira P; Bristol Myers Squibb, Princeton, New Jersey, USA., Lipton JH; Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada.

Publikováno v: British journal of haematology [Br J Haematol] 2023 Sep; Vol. 202 (5), pp. 942-952. Date of Electronic Publication: 2023 May 29.

Project Confirm: Accelerated Drug Approvals for Chronic Myeloid Leukemia.

Autor: Sweet KL; Moffitt Cancer Center, Tampa, Florida., Cortes JE; Georgia Cancer Center, Augusta University, Augusta, Georgia., Apperley JF; Centre for Haematology, Imperial College, London, United Kingdom., Mann M; Patient Advocate, Jonesboro, Georgia., Mauro MJ; Myeloproliferative Neoplasms Program, Memorial Sloan Kettering Cancer Center, New York City, New York., Oehler VG; Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle, Washington., Ruiz C; Patient Advocate, Los Angeles, California., Schiffer CA; Department of Hematology-Oncology, Karmanos Cancer Center at Wayne State University, Detroit, Michigan., Ehrlich LA; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Washington, DC., Pamuk GE; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Washington, DC., Wynne J; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Washington, DC., Mehta GU; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Washington, DC., de Claro RA; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Washington, DC., Theoret MR; Oncology Center of Excellence, U.S. Food and Drug Administration, Washington, DC., Smith BD; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland., Norsworthy KJ; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Washington, DC.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2023 Jun 13; Vol. 29 (12), pp. 2179-2183.